Intended for healthcare professionals

Clinical Research

United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results

Br Med J (Clin Res Ed) 1988; 296 doi: (Published 30 January 1988) Cite this as: Br Med J (Clin Res Ed) 1988;296:316
  1. Uk-Tia Study Group


    From 1979 to 1985, 2435 patients thought to have had a transient ischaemic attack or minor ischaemic stroke were allocated at random to receive long term blind treatment with either aspirin 600 mg twice daily (n=815), aspirin 300 mg once daily (806), or placebo (814). Treatment continued with about 85% compliance until September 1986 (mean four years). The odds of suffering one or more of four categories of event—namely, non-fatal myocardial infarction, non-fatal major stroke, vascular death, or non-vascular death—were 18% less in the two groups allocated to receive aspirin than in the group allocated to receive placebo (2p=0·01). The more relevant but less frequent composite event of disabling stroke or vascular death was reduced by only 7%; this reduction was not significantly different from zero, but nor was it significantly different from a 25% reduction. There was no definite difference between responses to the 300 mg and 1200 mg daily doses, except that the lower dose was significantly less gastrotoxic.

    Log in

    Log in through your institution


    * For online subscription